Zulfiyya Imamguliyeva
CancerSurgeryRadiation-induced cancerAndrogen deprivation therapySalivary gland cancerParticle therapyHormone therapySalivary duct carcinomaRadiation therapyMedicine
Publications 1
Clinical data of ri-SGCs patients treated between 2015 and 2019 at a tertiary cancer center and a national hadron therapy facility were reviewed. Latent time (LT) from first RT to ri-SGCs diagnosis, overall (OS), and disease-free survival (DFS) were assessed. Thirteen patients developed 14 ri-SGCs (one patient had 2 synchronous ri-SCGs), after a median LT of 23 years (range 16–34). Parotid was the primary site in 8 cases (57%) and salivary duct carcinoma was the most frequent histotype (29%). Ni...